﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Nickan Research Institute</PublisherName>
      <JournalTitle>Journal of Renal Injury Prevention</JournalTitle>
      <Issn>2345-2781</Issn>
      <Volume>4</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2015</Year>
        <Month>09</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>The effect of omega-3 on serum lipid profile in hemodialysis patients</ArticleTitle>
    <FirstPage>68</FirstPage>
    <LastPage>72</LastPage>
    <ELocationID EIdType="doi">10.12861/jrip.2015.14</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Hamid Reza</FirstName>
        <LastName>Omrani</LastName>
      </Author>
      <Author>
        <FirstName>Yahya</FirstName>
        <LastName>Pasdar</LastName>
      </Author>
      <Author>
        <FirstName>Daryosh</FirstName>
        <LastName>Raisi</LastName>
      </Author>
      <Author>
        <FirstName>Farid</FirstName>
        <LastName>Najafi</LastName>
      </Author>
      <Author>
        <FirstName>Ardeshir</FirstName>
        <LastName>Esfandiari</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.12861/jrip.2015.14</ArticleId>
    </ArticleIdList>
    <History>
    </History>
    <Abstract>Introduction: One of the major complications in hemodialysis patients is cardiovascular disease. Lipid abnormality is an important factor in the development of cardiovascular disease. Objectives: To investigate the effect of omega-3 supplementation on serum lipid profile in hemodialysis patients. Patients and Methods: This randomized clinical trial study included 2 groups of patients: those who received omega-3 supplementation (experimental group; 30 cases) and those who received placebo (control group; 30 cases). They received these for 10 weeks and serum lipid profile (triglyceride, high-density lipoprotein [HDL-C], low-density lipoprotein [LDL-C], and total cholesterol) was assessed 2 times, first before initiating supplementation and then at the end of 10-week study period. Results: Mean (±SD) serum total cholesterol levels at the beginning was 163 (±47) mg/dL in experimental group and 143 (±25) mg/dL in control group (P&gt; 0.05). These values decreased to 124 mg/dL and 132 mg/dL in control and experimental groups (P&lt; 0.05). There was no significant difference of HDL-C, LDL-C, or triglyceride levels between experimental and control groups after 10 weeks of treatment. Conclusion: Omega-3 supplementation in hemodialysis patients only showed significant decrease of serum total cholesterol level, but not other lipids.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Omega 3</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hemodialysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Serum lipids</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>